ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$16.16 USD
+0.60 (3.86%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $16.16 0.00 (0.00%) 6:34 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADMA 16.16 +0.60(3.86%)
Will ADMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Other News for ADMA
ADay Moving Average forms 180 Bearish Setup on September 17
Lower Bollinger Band Walk appears for ADay Moving Average after 2.55% move
ADay Moving Average makes New 52 Week Closing Low on September 15
Is ADay Moving Average showing downside potential? Lower Bollinger Band Walk shows up after a flat session
Stochastic Buy Signal appears for ADay Moving Average after 2.22% move